ADHD Treatment & Management for Pharmacists: A Focus on Osmotic vs. Non-Osmotic Drug Delivery Systems

Join Dr. Katzman in this accredited, on-demand webinar as he speaks about ADHD, a common, often lifelong neurodevelopmental disorder requiring accurate diagnosis, assessment of comorbidities, and a multimodal treatment approach. This webinar will highlight how pharmacists play a critical role in optimizing therapy, with long-acting stimulants recommended as first-line treatment per guidelines. A key focus is that not all extended-release methylphenidate formulations are therapeutically equivalent—particularly osmotic delivery systems—which significantly impact efficacy, stability, and patient outcomes.

Webinar presenter: Dr. Martin A. Katzman, MD, FRCP(C)

Learning Objectives:

1. Describe the features of Attention Deficit Hyperactivity Disorder (ADHD), subtypes and impact on patient risk and functionality
2. Apply the CADDRA guidelines recommendations for first-line treatment of ADHD
3. Identify Health Canada approved medications currently approved for use in ADHD
4. Assess evidence evaluating the pros and cons of non-osmotic versus osmotic drug delivery system

This learning activity has received financial support in the form of an unrestricted grant from Sun Pharma Canada Inc.